← Home / CG Oncology, Inc. (CGON)
Stock Analysis
CG Oncology, Inc. (CGON)
CGON
CGON · Market data
71.19 -2.52%
Track CGON in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when CGON price is:
52W Range Position
92%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-02 16:45 UTC
WOI Investment Thesis
Constructive
Confirmation improves above 75.24. Holding above 68.23 keeps the current thesis intact.
⚖️
✓
Fundamentals
Strong / Negative
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Breakout Confirmation
Pending
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
Structure remains valid above support.
68.23
↗
Break Above
Confirmation improves above resistance.
75.24
🎯
Next Objective
Pattern-derived target if setup continues.
—
×
Thesis Break
Scenario weakens below invalidation.
Below 68.23
Recent Company Events
SEC VERIFIED
Latest material filings
MAY
26
●
Management / Board
MEDIUM
CGON board and management update
Bellete Separation On May 20, 2026, CG Oncology, Inc.
8-K Filing • SEC EDGAR
MAY
8
●
Financial Results
HIGH
CG Oncology Reports First Quarter 2026 Financial Results and Provides Business Updates
(NASDAQ: CGON) today reported financial results for the first quarter ended March 31, 2026, and provided business updates.
8-K Filing • SEC EDGAR
What's Driving CGON?
📈 Technical recovery is improving
Momentum is Neutral. Watch 75.24 for confirmation and 68.23 for structure risk.
💼 Business quality remains relevant
Fundamentals remain relevant. Check growth, profitability, cash flow and balance sheet quality.
⚠️ Key risk remains
Below 68.23
Full Analysis Workspace
Technical Signal
Technical Setup Active
✓
An active technical structure is present. Use trigger, target, stop and watch levels for context.
Downtrend Structure
Downtrend line not broken yet · score 26
Trigger
73.43
RSI(14)
52.2
◎
How to read this setup
The nearest decision zone is framed by support around 68.23 and resistance near 73.43. A cleaner push through resistance would improve continuation odds, while a loss of support would weaken the current thesis.
Price Chart
CGON — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-07-31
Spec
Speculative premium
Valuation is very demanding relative to current fundamentals; expectations are high.
Market Cap
$6.3B
Company size
EV
$6.2B
Debt-adjusted value
P/E
-33.5
Not meaningful
P/B
5.7
Balanced
EV/EBIT
-29.0
Not meaningful
P/FCF
-39.1
Not meaningful
FCF Yield
-2.56%
Cash return
Source: SEC TTM data via WOI valuation cache Not financial advice
Business Lens
Financial pressure is elevated
Financial conditions require selective monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
1.08M
↗ Strong
📈 Net Income
-60.20M
↘ Negative
🧮 EPS (Basic)
-0.71
↘ Negative
CG Oncology, Inc.
Related Opportunities